Antonina A. Smetnik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antonina A. Smetnik has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Gennady Tikhonovich Sukhikh
National Medical Research Center for Obstetrics Gynecology and Perinatology Named after Academician V.I. Kulakov of the Ministry of Healthcare of Russian Federation, 117997 Moscow, Russia
12 shared publications - Tabeeva Giuzial
Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
10 shared publications - Elena N. Andreeva
Federal State Budgetary Educational Institution of Higher Education «Russian University of Medicine» of the Ministry of Health of Russia
9 shared publications - Mariya Igorevna Yarmolinskaya
D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russia
9 shared publications - Ivan Ivanovich Dedov
Endocrinology Research Centre
8 shared publications - Madina R. Dumanovskaya
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
8 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 760
Wnt Signaling in Endometriosis: Mechanisms and Therapeutic Potential
Endometriosis is a chronic, estrogen-dependent disease that affects up to 10% of women of reproductive age and leads to pain, infertility, and impaired quality of life. Despite current hormonal and surgical therapies, many patients continue to suffer from recurrence, fibrosis, and reduced fertility, emphasizing the need for mechanism-based treatment strategies. Aberrant intracellular signaling contributes to a pathogenic network linking proliferation, inflammation, fibrotic remodeling, and therapeutic resistance. Focusing on the roles of the Wnt/β-catenin pathway, we discuss recent studies that indicate that excessive Wnt signaling may upregulate these disease-relevant cellular programs, while inhibition of the pathway may reduce the endometriotic lesion burden and fibrosis in preclinical models. Advances in Wnt-targeted therapies in oncology and fibrotic diseases now provide a timely translational framework for endometriosis. Targeting the Wnt pathway as part of broader mechanism-based therapeutic strategies may enable a shift from symptomatic treatments to non-hormonal and disease-modifying approaches.
- 7 November 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 760
Open AccessWnt Signaling in Endometriosis: Mechanisms and Therapeutic Potential
Endometriosis is a chronic, estrogen-dependent disease that affects up to 10% of women of reproductive age and leads to pain, infertility, and impaired quality of life. Despite current hormonal and surgical therapies, many patients continue to suffer from recurrence, fibrosis, and reduced fertility, emphasizing the need for mechanism-based treatment strategies. Aberrant intracellular signaling contributes to a pathogenic network linking proliferation, inflammation, fibrotic remodeling, and therapeutic resistance. Focusing on the roles of the Wnt/β-catenin pathway, we discuss recent studies that indicate that excessive Wnt signaling may upregulate these disease-relevant cellular programs, while inhibition of the pathway may reduce the endometriotic lesion burden and fibrosis in preclinical models. Advances in Wnt-targeted therapies in oncology and fibrotic diseases now provide a timely translational framework for endometriosis. Targeting the Wnt pathway as part of broader mechanism-based therapeutic strategies may enable a shift from symptomatic treatments to non-hormonal and disease-modifying approaches.
- 31 August 2026
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 8_2026, 143-153
Efficacy of progestogen therapy for extragenital endometriosis: clinical outcomes and MRI-detected changes in lesion characteristics
- 31 August 2026
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 8_2026, 143-153
Efficacy of progestogen therapy for extragenital endometriosis: clinical outcomes and MRI-detected changes in lesion characteristics
- 31 July 2026
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 7_2026, 38-46
Genitourinary syndrome of menopause: the role of androgens in current understanding of pathogenesis, proteomic data and new therapeutic opportunities
- 31 July 2026
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 7_2026, 38-46
Genitourinary syndrome of menopause: the role of androgens in current understanding of pathogenesis, proteomic data and new therapeutic opportunities
- Open Access
Factors Associated with Live Birth After Placenta-Derived Mesenchymal Stromal Cell Therapy in Women with Recurrent Intrauterine Adhesions and Thin Endometrium
Recurrent intrauterine adhesions (IUA) and refractory thin endometrium are associated with impaired endometrial regeneration, reduced implantation, and poor live birth outcomes. Regenerative therapy using mesenchymal stromal cells (MSCs) has shown promising results; however, factors associated with reproductive success remain unclear. In this prospective, single-centre, single-arm uncontrolled observational study, 35 women with recurrent IUA and thin endometrium (p = 0.04), lower baseline RI in uterine, arcuate and radial arteries, and higher baseline AMH (OR 2.59 per doubling; 95% CI 1.15–6.89) were significantly associated with live birth. Endometrial thickness increased after therapy but was not significantly associated with live birth. No severe adverse events were observed. Placenta-derived MSC therapy was followed by live birth in 31.4% of women with recurrent IUA and refractory thin endometrium. A shorter duration of reproductive disorders, less severe adhesions, lower baseline RI in uterine, arcuate and radial arteries, and higher AMH levels were associated with live birth after treatment and may help identify patients with a more favourable reproductive prognosis in future controlled studies.
Open AccessFactors Associated with Live Birth After Placenta-Derived Mesenchymal Stromal Cell Therapy in Women with Recurrent Intrauterine Adhesions and Thin Endometrium
Recurrent intrauterine adhesions (IUA) and refractory thin endometrium are associated with impaired endometrial regeneration, reduced implantation, and poor live birth outcomes. Regenerative therapy using mesenchymal stromal cells (MSCs) has shown promising results; however, factors associated with reproductive success remain unclear. In this prospective, single-centre, single-arm uncontrolled observational study, 35 women with recurrent IUA and thin endometrium (p = 0.04), lower baseline RI in uterine, arcuate and radial arteries, and higher baseline AMH (OR 2.59 per doubling; 95% CI 1.15–6.89) were significantly associated with live birth. Endometrial thickness increased after therapy but was not significantly associated with live birth. No severe adverse events were observed. Placenta-derived MSC therapy was followed by live birth in 31.4% of women with recurrent IUA and refractory thin endometrium. A shorter duration of reproductive disorders, less severe adhesions, lower baseline RI in uterine, arcuate and radial arteries, and higher AMH levels were associated with live birth after treatment and may help identify patients with a more favourable reproductive prognosis in future controlled studies.
- 11 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 153-161
Comprehensive approach to managing climacteric syndrome considering new pathogenetic mechanisms: Therapy and prevention
Climacteric Syndrome (CS) is a complex condition that extends beyond vasomotor symptoms (VMS) to include psychoemotional disorders, sleep disturbances, metabolic dysfunctions, and increased risks of somatic pathology. These changes affect up to 97.5% of women during peri- and postmenopause, impairing quality of life and elevating the risks of cardiovascular, neurodegenerative, and oncological diseases. This review provides analysis of current data from international electronic bibliographic and scientific databases (PubMed, Scopus, Web of Science, eLIBRARY.RU), as well as Cochrane Library and peer-reviewed medical journals. It focuses on several insufficiently elucidated pathophysiological aspects of postmenopausal disturbances, including the mechanisms of narrowing the hypothalamic thermoneutral zone, dysfunction of the serotonergic and noradrenergic neurotransmitter systems, the role of oxidative stress and decreased antioxidant enzyme activity, DNA damage and carcinogenesis, and the development of dyslipidemia, insulin resistance, and endothelial dysfunction. The review provides a detailed argument for the necessity of implementing a comprehensive therapeutic approach to CS, aimed not at isolated symptom relief but at the simultaneous correction of key interconnected pathogenetic links. It presents a detailed analysis of modern fundamental and clinical data demonstrating the efficacy of various active molecules, including β-alanine, isoflavones, 5-hydroxytryptophan, and vitamins C, E, and B. Their effects are examined in terms of stabilizing the thermoregulation center in the hypothalamus, selective modulation of estrogen receptors, improving lipid profile and insulin sensitivity, as well as restoring serotonin levels, homocysteine balance, and suppressing oxidative stress. This multicomponent patient management strategy ensures not only effective symptomatic control of vasomotor and psychoemotional manifestations of CS but also long-term prevention of cardiovascular, metabolic, and neurodegenerative complications, aligning with the principles of women’s active longevity.
- 11 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 153-161
Comprehensive approach to managing climacteric syndrome considering new pathogenetic mechanisms: Therapy and prevention
Climacteric Syndrome (CS) is a complex condition that extends beyond vasomotor symptoms (VMS) to include psychoemotional disorders, sleep disturbances, metabolic dysfunctions, and increased risks of somatic pathology. These changes affect up to 97.5% of women during peri- and postmenopause, impairing quality of life and elevating the risks of cardiovascular, neurodegenerative, and oncological diseases. This review provides analysis of current data from international electronic bibliographic and scientific databases (PubMed, Scopus, Web of Science, eLIBRARY.RU), as well as Cochrane Library and peer-reviewed medical journals. It focuses on several insufficiently elucidated pathophysiological aspects of postmenopausal disturbances, including the mechanisms of narrowing the hypothalamic thermoneutral zone, dysfunction of the serotonergic and noradrenergic neurotransmitter systems, the role of oxidative stress and decreased antioxidant enzyme activity, DNA damage and carcinogenesis, and the development of dyslipidemia, insulin resistance, and endothelial dysfunction. The review provides a detailed argument for the necessity of implementing a comprehensive therapeutic approach to CS, aimed not at isolated symptom relief but at the simultaneous correction of key interconnected pathogenetic links. It presents a detailed analysis of modern fundamental and clinical data demonstrating the efficacy of various active molecules, including β-alanine, isoflavones, 5-hydroxytryptophan, and vitamins C, E, and B. Their effects are examined in terms of stabilizing the thermoregulation center in the hypothalamus, selective modulation of estrogen receptors, improving lipid profile and insulin sensitivity, as well as restoring serotonin levels, homocysteine balance, and suppressing oxidative stress. This multicomponent patient management strategy ensures not only effective symptomatic control of vasomotor and psychoemotional manifestations of CS but also long-term prevention of cardiovascular, metabolic, and neurodegenerative complications, aligning with the principles of women’s active longevity.
- Open Access
- 26 April 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- No. 1,p. 40-69
Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice
- 26 April 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- No. 1,p. 40-69
Open AccessRussian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice
- Open Access
- 15 February 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (1) , 6-27
Menopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists
More than one million women in Russia enter menopause each year. The severe estrogen deficiency associated with this transition causes symptoms that significantly impair quality of life and contribute to an increased risk of cardiovascular and metabolic diseases. Menopausal hormone therapy (MHT) is the established standard of care for menopausal symptoms. On the initiative of several professional societies (the Russian Society of Obstetricians and Gynecologists, the Russian Society of Cardiology, the Russian Association of Endocrinologists, the Eurasian Association of Therapists, the Russian Society of Gynecological Endocrinology and Menopause, the Russian Association of Gerontologists and Geriatricians, the Association of Phlebologists of Russia), a Delphi panel was convened to develop a multidisciplinary expert consensus on MHT for patients with cardiovascular and metabolic diseases. The goal was to enhance research and clinical approaches to managing menopausal women. A consensus was reached at the end of the first Delphi round. The experts agreed that initiating MHT requires a thorough assessment of individual risks, including cardiovascular health and comorbidities. MHT can offset metabolic and cardiovascular risk factors in peri- and postmenopausal women by normalizing the lipid profile, improving carbohydrate metabolism, and reducing insulin resistance. An interdisciplinary approach allows for personalized MHT, minimizes potential complications, improves the quality of life for peri- and postmenopausal women, and promotes active longevity.
- 15 February 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (1) , 6-27
Open AccessMenopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists
More than one million women in Russia enter menopause each year. The severe estrogen deficiency associated with this transition causes symptoms that significantly impair quality of life and contribute to an increased risk of cardiovascular and metabolic diseases. Menopausal hormone therapy (MHT) is the established standard of care for menopausal symptoms. On the initiative of several professional societies (the Russian Society of Obstetricians and Gynecologists, the Russian Society of Cardiology, the Russian Association of Endocrinologists, the Eurasian Association of Therapists, the Russian Society of Gynecological Endocrinology and Menopause, the Russian Association of Gerontologists and Geriatricians, the Association of Phlebologists of Russia), a Delphi panel was convened to develop a multidisciplinary expert consensus on MHT for patients with cardiovascular and metabolic diseases. The goal was to enhance research and clinical approaches to managing menopausal women. A consensus was reached at the end of the first Delphi round. The experts agreed that initiating MHT requires a thorough assessment of individual risks, including cardiovascular health and comorbidities. MHT can offset metabolic and cardiovascular risk factors in peri- and postmenopausal women by normalizing the lipid profile, improving carbohydrate metabolism, and reducing insulin resistance. An interdisciplinary approach allows for personalized MHT, minimizes potential complications, improves the quality of life for peri- and postmenopausal women, and promotes active longevity.
- Open Access
- 18 January 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (6) , 108-137
Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice.
- 18 January 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (6) , 108-137
Open AccessRussian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice.
- Open Access
- 11 January 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (4) , 21-37
Сlinical recommendations of RSOG "Menopause and climacteric period among females. Version of year 2025"
The present article contains the most actual version of Russian national clinical recommendations (Version of year 2025) "Menopause and climacteric period among females" In case of ignoring timely sex steroid replacement therapy menopause can decrease chances for achieving healthy longevity and ageing. This document has been provided by members of Russian Society of Obstetricicians and Gynaecologists (RSOG). The next revision is planned for year 2027 or earlier. The document has been approved by scientific practical council of the Russian Ministry of Health.
- 11 January 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (4) , 21-37
Open AccessСlinical recommendations of RSOG "Menopause and climacteric period among females. Version of year 2025"
The present article contains the most actual version of Russian national clinical recommendations (Version of year 2025) "Menopause and climacteric period among females" In case of ignoring timely sex steroid replacement therapy menopause can decrease chances for achieving healthy longevity and ageing. This document has been provided by members of Russian Society of Obstetricicians and Gynaecologists (RSOG). The next revision is planned for year 2027 or earlier. The document has been approved by scientific practical council of the Russian Ministry of Health.